| 方志荣,陆金鑫,孙双涛,等.氟哌噻吨美利曲辛治疗良性阵发性位置性眩晕成功复位后残余头晕的疗效观察[J].安徽医药,2021,25(9):1878-1880. |
| 氟哌噻吨美利曲辛治疗良性阵发性位置性眩晕成功复位后残余头晕的疗效观察 |
| Effect of Flupentixol and Melitracen on residual dizziness after successful canalith repositioning manneuvers in patients with BPPV |
| |
| DOI：10.3969/j.issn.1009-6469.2021.09.043 |
| 中文关键词: 良性阵发性位置性眩晕 残余头晕 氟哌噻吨美利曲辛 |
| 英文关键词: Benign paroxymal positional vertigo Residual dizziness Flupentixol and Melitracen tablets |
| 基金项目: |
|
| 摘要点击次数: 1746 |
| 全文下载次数: 454 |
| 中文摘要: |
| 目的观察氟哌噻吨美利曲辛对良性阵发性位置性眩晕( BPPV)成功耳石复位后残余头晕的疗效。方法将 2018年 6月至 2019年 5月在东部战区海军医院 84例 BPPV成功复位后残余头晕的病人以随机数字表法分为对照组及治疗组(各 42例)对照组给予甲磺酸倍他司汀片治疗，治疗组给予甲磺酸倍他司汀片 +氟哌噻吨美利曲辛治疗，疗程 14 d，于治疗后第 1天、第 7天、，第 14天行医院焦虑抑郁量表( HADS)、眩晕障碍量表(DHI)评分。结果对照组 4例失访，治疗组 1例失访。治疗后第 7天及第 14天，治疗组 DHI总分［(13.76±6.08)分、(8.82±4.88)分］、 HADS的焦虑［(6.62±2.57)分、(4.56±2.52分)］、抑郁［(4.75±3.08)分、(3.86±2.27)分］评分均低于对照组［( 21.05±6.23)分、(12.06±6.02)分；(8.28±3.16)分、(6.48±2.83分)；(6.34±2.87)分、(5.76±2.38)分］(P<0.05)。对照组无不良反应，治疗组出现 4例轻微症状反应，未给予特殊治疗。结论残余头晕病人伴有焦虑抑郁，通过抗焦虑、抗抑郁治疗，氟哌噻吨美利曲辛可以减轻 BPPV病人成功复位后残余头晕症状。 |
| 英文摘要: |
| Objective To evaluate the efficacy of Flupentixol and Melitracen on residual dizziness (RD) after successful canalith repositioning maneuvers (CRPs) in patients with benign paroxysmal positional vertigo (BPPV).Methods Eighty-four patients with RD after successful CRPs in Naval Hospital of Easter Theater PLA from June 2018 to May 2019 were randomly divided into control groupand study group, with 42 cases in each group. The control group was treated with Betastine mesylate tablets, while the study group wastreated with Flupentixol and Melitracen tablets on the basis of Betastine mesylate tablets. The course of treatment lasted for 14 days,and the dizziness handicap inventory (DHI), hospital anxiety and depress scale (HADS) were evaluated on day 1, day 7 and day 14 aftertreatment.Results Four cases in the control group and 1 case in the study group were lost to follow-up. On day 7 and 14 after treatment, the total scores of DHI [(13.76±6.08), (8.82±4.88)] and HADS [(6.62±2.57), (4.56±2.52)], depression [(4.75±3.08), (3.86±2.27)]in study group were lower than those of the control group [(21.05±6.23), (12.06±6.02) ; (8.28±3.16), (6.48±2.83); (6.34±2.87), (5.76±2.38)] (P<0.05). There were no adverse reactions in the control group, and 4 cases in the study group were with mild symptoms, and nospecial treatment was given.Conclusions The patients with RD are often accompanied by symptoms of anxiety and depression. Flupentixol and Melitracen tablets could alleviate RD and improve quality of life by anti-anxiety and anti-depression in BPPV patients after successful CRPs. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
